年龄对单吸入器三联疗法疗效与安全性影响:IMPACT试验事后分析
基于IMPACT试验的事后分析,评估年龄对氟替卡松糠酸酯/乌美溴铵/维兰特罗(FF/UMEC/VI)单吸入器三联疗法疗效与安全性的影响。纳入10,355例有症状且既往有急性加重史的COPD患者,随机接受FF/UMEC/VI、FF/VI或UMEC/VI治疗52周。结果显示,在多数终点上,FF/UMEC/VI较FF/VI和UMEC/VI降低中/重度急性加重率、改善肺功能与健康状态,且不受年龄影响,安全性相似。
要点
- FF/UMEC/VI较FF/VI和UMEC/VI降低中/重度急性加重率,65岁以上亚组降幅更明显。
- FF/UMEC/VI在全部年龄亚组均改善 trough FEV1 和 SGRQ 应答率。
- 各年龄亚组安全性相似,未发现新的安全性信号。
核心结论
- FF/UMEC/VI在多数终点上降低中/重度急性加重率并改善肺功能与健康状态,且不受年龄影响,安全性相似。
研究设计与样本
- IMPACT试验为III期双盲52周研究,患者随机2:2:1接受FF/UMEC/VI 100/62.5/25 μg、FF/VI 100/25 μg或UMEC/VI 62.5/25 μg。
- 纳入≥40岁、有症状且既往一年≥1次中/重度急性加重的COPD患者,意向治疗人群10,355例。
- 年龄分布:≤64岁4,724例(46%),65-74岁4,225例(41%),≥75岁1,406例(14%)。
主要发现
- 第52周 trough FEV1 较基线变化和SGRQ应答者比例的事后分析显示,FF/UMEC/VI在所有亚组均显著优于FF/VI或UMEC/VI。
- 未发现新的安全性信号。
临床怎么用
- 对于有症状且既往有急性加重史的COPD患者,FF/UMEC/VI三联疗法在不同年龄组均可降低中/重度急性加重率并改善肺功能与健康状态。
局限性
- 本文为IMPACT试验的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the Informing the Pathway of COPD Treatment (IMPACT) trial, single-inhaler triple-therapy fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) reduced moderate/severe exacerbation rates vs FF/VI and UMEC/VI in patients with symptomatic COPD and a history of exacerbations, with a similar safety profile. RESEARCH QUESTION: Are trial outcomes with single-inhaler triple-therapy FF/UMEC/VI vs FF/VI and UMEC/VI affected by age in patients with symptomatic COPD and a history of exacerbations? STUDY DESIGN AND METHODS: IMPACT was a phase III, double-blind, 52-week trial. Patients ≥ 40 years of age with symptomatic COPD and ≥ 1 moderate/severe exacerbation in the previous year were randomly assigned 2:2:1 to FF/UMEC/VI 100/62.5/25 μg, FF/VI 100/25 μg, or UMEC/VI 62.5/25 μg. End points assessed by age included annual rate of moderate/severe exacerbations, change from baseline (CFB) in trough FEV1, proportion of St. George's Respiratory Questionnaire (SGRQ) responders (≥ 4 units decrease from baseline in SGRQ total score), and safety. RESULTS: The intention-to-treat population comprised 10,355 patients; 4,724 (46%), 4,225 (41%), and 1,406 (14%) were ≤ 64, 65 to 74, and ≥ 75 years of age, respectively. FF/UMEC/VI reduced on-treatment moderate/severe exacerbation rates vs FF/VI (% reduction [95% CI]: ≤ 64 years, 8% [-1 to 16]; P = .070; 65-74 years, 22% [14-29]; P < .001; ≥ 75 years, 18% [3-31]; P = .021) and vs UMEC/VI (≤ 64 years, 16% [7-25]; P = .002; 65-74 years, 33% [25-41]; P < .001; ≥ 75 years, 24% [6-38]; P = .012), with greatest rate reduction seen in the 65 to 74 and ≥ 75 years subgroups. Post hoc analyses of CFB in trough FEV1 and proportion of SGRQ responders at week 52 were significantly greater with FF/UMEC/VI than with FF/VI or UMEC/VI in all subgroups. No new safety signals were identified. INTERPRETATION: FF/UMEC/VI reduced the rate of moderate/severe exacerbations and improved lung function and health status vs FF/VI and UMEC/VI irrespective of age for most end points, with a similar safety profile. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT02164513; URL: www.clinicaltrials.govCTT116855.
引用
- Hanania NA, Mannino DM, Criner GJ, et al. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. Chest. 2020. PMID: 33031829. doi:10.1016/j.chest.2020.09.253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。